IVIM Health vs Brello: verified ratings, pricing, and protocols
Quick verdict: For readers prioritizing verified third-party ratings, explicit pricing and a documented clinician-guided protocol, IVIM Health is the clearer option based on the captured evidence; Brello’s captured page lacked verifiable pricing and details.
IVIM Health vs Brello: headline differences up front
The comparison IVIM Health vs Brello centers on five distinctive differences supported by the captured evidence: third-party ratings and trust signals, published pricing and promotional offers, the presence of a proprietary protocol and internal outcome claims, the role of compounded medications and regulatory notes, and the amount of verifiable public detail captured for each provider.
1) Third-party ratings and trust signals
IVIM Health: documented 4.9-star ratings on both Google and Trustpilot, described as a rare dual third-party verification in this market. Brello: no third-party ratings were captured or verified on the landing-page evidence supplied.
2) Pricing transparency and promotional offers
IVIM Health: the capture shows Semaglutide listed at $75/mo, Tirzepatide at $133/mo, plus a $74.99/mo program fee, and promotional language including a Free Month Membership with code GIFT75 and a no-obligation free consultation valued at $75. The IVIM FAQ in the capture also states first-month pricing as $99 and $174/month ongoing in other captured lines; these varied price points are presented on IVIM’s captured pages. Brello: pricing details were not published or could not be verified on the captured affiliate landing page.
3) Protocol claims and clinical evidence
IVIM Health: the capture describes a proprietary GLP-1 ID clinician-guided protocol and cites internal publications and retrospective observational studies in Obesity Pillars reporting outcomes; the material notes that those are not randomized head-to-head trials and that results may vary. Brello: no captured clinical outcome claims were available on the provided landing-page evidence.
4) Compounded medications and regulatory notes
Both captures emphasize the relevance of medication approval status. IVIM’s captured material explicitly states its compounded products are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Brello’s captured note states that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Both providers require clinician review before treatment is appropriate.
5) Verified detail and captured evidence
IVIM Health: multiple specific elements were captured, including ratings, pricing lines, promotional codes and study references. Brello: the captured affiliate landing page did not yield readable pricing, eligibility, pharmacy, or detailed service descriptions, and many details are listed as not verified.
Side-by-side snapshot
| Criteria | IVIM Health | Brello |
|---|---|---|
| Starting price (captured) | Semaglutide $75/mo; Tirzepatide $133/mo; plus $74.99/mo program fee; code GIFT75 for free month | Not verified on captured page |
| Third-party ratings | 4.9 stars on Google and Trustpilot (captured) | Not captured or verified |
| Protocol and outcome claims | Proprietary GLP-1 ID protocol; internal study references and observational data cited; not head-to-head | No clinical outcomes captured |
| Compounded medication note | Compounded formulations used; explicitly not FDA-approved and not reviewed by FDA | Compounded medications, when offered, are not FDA-approved; capture lacked further detail |
| Availability and verification | Multiple captured details; not available in all states; RX required after clinician evaluation | Pricing, eligibility, pharmacy, and state coverage not verified on capture |
What this means for you
If you value clearly captured pricing, a documented promotional offer and independent third-party ratings, IVIM Health has those elements in the captured evidence. If you need to confirm exact eligibility, medication form, total cost, renewal terms and state availability before enrollment, the Brello capture recommends confirming those items as the landing-page capture did not verify them.
Safety and regulatory reminders
Both providers’ captures indicate clinician review is required to determine medical appropriateness. IVIM’s captured material repeatedly warns that compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. Brello’s captured note likewise states compounded medications, when offered, are not FDA-approved.
Final take on IVIM Health vs Brello
Based solely on the captured evidence, IVIM Health provides more verifiable public details: dual 4.9-star ratings, explicit pricing lines, a free-month code GIFT75 and a proprietary GLP-1 ID protocol with internal study citations. Brello’s captured page did not publish verifiable pricing, eligibility, pharmacy or renewal details in the evidence supplied, and therefore requires prospective patients to confirm those items live with Brello before enrolling.
Choose IVIM Health if…
you prioritize documented third-party ratings, captured pricing and a clinician-guided proprietary protocol supported by internal observational studies, and you want the captured promotional option of a free month with code GIFT75 plus a no-obligation consultation.
Choose Brello if…
you need to confirm eligibility, medication form, total cost, renewal terms and state availability directly with the provider because those specific details were not verified in the captured landing-page evidence.
Ready to Compare Telehealth Providers?
Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.
Compare All Providers →More comparisons
